YOLFTbeta
47

Meribank Biotech Co., Ltd

4724 · TWO · Healthcare / Biotechnology

9.28TWD-0.06 (-0.64%)

Price History

Full chart

Market Stats

Previous Close9.34
Open9.34
Day Range8.82 – 9.34
52-Week Range7.94 – 17.40
Volume81.07K
Market Cap983.76M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.43
Dividend Yield0.00%
Beta0.44
50-Day Avg9.06
200-Day Avg12.27

About

Meribank Biotech Co., Ltd researches, develops, manufactures, and stores mesenchymal stem cells in Taiwan. The company engages in the detection, extraction, cryopreservation, archiving, and storage of umbilical cord blood, placental and umbilical cord mesenchymal stem cells, adult peripheral blood stem cells, and immune cells. It also provides cell cryopreservation services. The company was founded in 2001 and is based in Taipei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Jian-Fang Cai
  • HeadquartersNo.68, Neihu Road, Taipei, Taiwan, 11493, Taiwan
  • Websitehttps://www.meribank.com.tw

Leadership

  • Mr. Jian-Fang CaiManager & Vice Chairman
  • Yuxia ChenAccounting Supervisor

Financials

Income Statement

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue160.95M194.39M163.08M180.12M234.34M366.43M471.76M
Growth (%)-+20.78%-16.11%+10.45%+30.10%+56.37%+28.75%
Cost of Revenue67.92M79.25M73.02M85.35M95.47M172.49M269.59M
Gross Profit93.03M115.14M90.06M94.77M138.87M193.94M202.18M
Gross Margin57.80%59.23%55.22%52.61%59.26%52.93%42.86%
Operating Expense150.45M185.25M187.27M204.55M262.02M280.61M249.50M
Operating Income-57.41M-70.11M-97.22M-109.78M-123.15M-86.67M-47.32M
Operating Margin-35.67%-36.07%-59.62%-60.95%-52.55%-23.65%-10.03%
EBITDA-47.19M-29.95M-68.60M-64.66M-92.56M-6.83M89.59M
EBITDA Margin-29.32%-15.41%-42.07%-35.90%-39.50%-1.86%18.99%
Net Income-59.90M-54.46M-99.19M-102.13M-125.35M-94.71M-81.47M
Net Income Margin-37.22%-28.01%-60.83%-56.70%-53.49%-25.85%-17.27%
R&D4.87M6.43M16.11M25.94M35.48M35.90M31.26M
R&D as % of Total Revenue3.03%3.31%9.88%14.40%15.14%9.80%6.63%
Interest Expense554.00K742.00K1.13M985.00K847.00K10.70M23.11M
Interest Expense % of Total Revenue0.34%0.38%0.69%0.55%0.36%2.92%4.90%

Balance Sheet

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets693.07M729.97M947.32M846.33M1.06B2.68B2.88B
Total Liabilities258.71M347.34M361.27M372.53M390.81M1.46B1.62B
Total Equity434.36M382.64M586.05M471.20M661.73M1.21B1.25B
Cash55.17M51.40M192.15M85.16M399.46M165.09M97.44M
Total Debt18.68M69.92M52.97M45.83M34.04M942.84M-
Net Debt-36.48M18.52M-139.18M-39.33M-365.42M777.75M65.44M

Cash Flow

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.74M-17.74M-23.00M-41.33M-29.70M-38.09M89.45M
Investing Cash Flow4.97M24.18M-118.07M-45.01M48.15M-362.46M-
Financing Cash Flow-7.29M-10.22M281.82M-20.66M295.85M166.17M-
Capital Expenditure5.28M7.53M7.52M4.25M6.68M344.19M4.89M
Free Cash Flow-9.02M-25.26M-30.52M-45.58M-36.38M-382.28M84.57M
FCF to OCF241.10%142.44%132.71%110.28%122.49%1003.72%94.54%

Key Statistics & Ratios

Market Cap983.76M
Enterprise Value1.74B
Trailing P/E0.00
Forward P/E0.00
Price / Sales2.41
Price / Book0.72
EPS-1.43
Book Value12.27
Revenue (TTM)408.48M
Gross Profit (TTM)142.93M
EBITDA-45.45M
Profit Margin-33.07%
Operating Margin-34.91%
Return on Equity-11.33%
Return on Assets-2.37%
Shares Outstanding95.98M
Shares Float45.14M
Beta0.44
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%